866... in December, it was the center of the universe.
A couple of months ago, it was "best in class", and Kirkman said that they had been most excited, all along and from "preclinical" observations, about head and neck.
Yesterday, we got what was supposed to be a pipeline update. And 866 got a few seconds, thrown in at the end of discussion. No clarity, despite existing data from two relatively large phase II trials. Just a "oh yeah, don't forget about 866" vomit at the end.
So, is there something really embarrassing on the table, something that reflects on Williams, Henney et al.? They took it to a comprehensive phase II program before assuring that they could scale up the isolation chem? Etc.? Something so embarrassing that they now want to just keep quiet about their savior?
Shareholders deserve data. Kirkman touts 866 and instructs looking forward to 4Q13 results, but withholds 866 data from completed trials. Those who were listening to a ONTY call for the first time yesterday? They'd have no clue that the molecule had just failed to advance for prostate, glioblastoma, CRC and NSCLC.
So how can the Board continue to expose the company to this sort of liability? Lies and (very) active deceptions? |
